Graybug Vision commences Phase 2b Clinical study to target wet AMD
Category: #health  By Pankaj Singh  Date: 2019-10-04
  • share
  • Twitter
  • Facebook
  • LinkedIn

Graybug Vision commences Phase 2b Clinical study to target wet AMD

Macular degeneration is the leading cause of irreversible, serious vision loss that occurs when a section of the retina known as the macula is damaged. It is often observed that Age-Related Macular Degeneration (AMD) is commonly occurred in older white Americans. Growing cases of wet AMD has led several pharma companies to develop novel therapies, however, are still in clinical stages.

Graybug Vision, Inc., has recently made some advancement in this field when it initiated its Phase 2b trial (ALTISSIMO) for GB-102 for patients who suffer from wet AMD. Although, the current available treatment for wet AMD has given some encouraging results, the frequent shots of IVT (intravitreal) injections are very torturous for patients, as well as for their treating physicians and caregivers.

To tackle this, GB-102, a twice-per-year therapy and a pan-VEGF receptor inhibitor, was created with an aim to minimize the need for constant IVT injections in retinal diseases, such as DME, RVO and wet AMD.

The drug hopes to cut the substantial treatment burden and sub-optimal visual results faced in day-to-day practice because of the difficulties patients experience while meeting the retinal specialist numerous times in a year just for eye examinations and injections.

Incidentally, this positive news comes on heels at the time of some recent changes in management. Earlier this year, the Board of Directors had decided to position Frédéric Guerard as the Chief Executive Officer of Graybug Vision. 

According to reliable sources, Mr. Guerard has 20 years of a very successful career record in the pharmaceutical industry and has taken up several roles in Greybug which include strategic, commercial and multiple leadership roles. 

As for the recent trial, Graybug Vision has finalized a GB-102 Phase 1/2a study (ADAGIO) in Q1 2019 which met its primary endpoint of tolerability and safety, and was validated to be a durable biological signal of 6 months or more from a single IVT injection in patients with wet AMD. GB-102 is also being tested in an ongoing Phase 2a study in patients with macular edema secondary to RVO or DME.

Source Credit: https://graybug.com/graybug-vision-initiates-phase-2b-altissimo-clinical-trial-of-gb-102-in-patients-with-wet-age-related-macular-degeneration/

 



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Vertex announces reimbursement of ORKAMBI and SYMDEKO in Australia
Vertex announces reimbursement of ORKAMBI and SYMDEKO in Australia
By Pankaj Singh

Vertex Pharmaceuticals Inc. is a global biopharmaceutical company that is relentless in striving for medical excellence while developing transformative therapies for life-threatening and serious diseases, such as cysti...

Centene, RxAdvance and Walgreens unveil new pharmacy management model
Centene, RxAdvance and Walgreens unveil new pharmacy management model
By Pankaj Singh

The cloud adoption trend is increasingly picking up momentum across a plethora of industry disciplines. Among these, the healthcare and pharmaceutical sector is emerging as a prominent cloud subscriber globally. Numero...

Incyte unveils positive results from Phase 2 ruxolitinib cream study
Incyte unveils positive results from Phase 2 ruxolitinib cream study
By Pankaj Singh

Vitiligo is a prominent skin diseases prevalent across the world that causes skin color loss. The disease is increasingly being taken as a serious issue by various pharmaceutical firms across the globe, who are continu...